Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biote Corp. - Class A common stock (NQ: BTMD )

5.480 UNCHANGED
Streaming Delayed Price Updated: 11:15 AM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biote Corp. - Class A common stock

< Previous 1 2 Next >
Biote Reports Third Quarter 2023 Financial Results
From Biote
Via Business Wire
Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call
From biote Corp.
Via Business Wire
Biote Reports Second Quarter 2023 Financial Results
From Biote
Via Business Wire
Biote Schedules Second Quarter 2023 Financial Results Release and Conference Call
From biote Corp.
Via Business Wire
Biote Formalizes Commitment to Men’s Hormone Health With Launch of New Men’s Health Division
From biote Corp.
Via Business Wire
InvestorNewsBreaks – Biote Corp. (NASDAQ: BTMD) Closes $31M Underwritten Public Offering
Via Investor Brand Network
Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
From Biote
Via Business Wire
Biote Announces Pricing of Secondary Offering of Common Stock
From biote Corp
Via Business Wire
Biote to Participate at Upcoming Investor Conferences
From biote Corp.
Via Business Wire
Biote Appoints Mary J. Puncochar as Chief Commercial Officer
From biote Corp.
Via Business Wire
Biote Reports First Quarter 2023 Financial Results
From Biote
Via Business Wire
Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
From Biote
Via Business Wire
Biote Schedules First Quarter 2023 Financial Results Release and Conference Call
From biote Corp.
Via Business Wire
Biote Names John Denne as General Manager, Men’s Health Division
From Biote
Via Business Wire
Biote Reports Fourth Quarter and Full Year 2022 Financial Results
From Biote
Via Business Wire
Study: Testosterone Pellet Therapy Significantly Improves Bone Density in Male Patient Case Report
From Biote
Via Business Wire
Biote to Present at 35th Annual Roth Conference
From biote Corp.
Via Business Wire
Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call
From Biote Corp.
Via Business Wire
Biote Announces Closing of Secondary Offering of 8,500,000 Shares of Common Stock Including Full Exercise of the Underwriters’ Over-Allotment Option
From biote Corp.
Via Business Wire
Biote Announces Pricing of Secondary Offering of Common Stock
From biote Corp
Via Business Wire
Biote to Present at Jefferies London Healthcare Conference
From biote Corp.
Via Business Wire
Biote Reports Third Quarter Financial Results
From Biote
Via Business Wire
Biote Appoints Debby Morris to Board of Directors
From biote Corp.
Via Business Wire
Biote Schedules Third Quarter 2022 Financial Results Release and Conference Call
From biote Corp.
Via Business Wire
Biote Releases Updated Corporate Presentation for October 2022
From biote Corp
Via Business Wire
Biote Announces Strategic Partnership with IMAC Holdings, Inc.
From biote Corp.
Via Business Wire
Biote Announces Approval to Relist on The Nasdaq Stock Market
From Biote Corp.
Via Business Wire
Biote Appoints Samar Kamdar as Chief Financial Officer
From Biote
Via Business Wire
Biote Issues Correction to Second Quarter Operating Loss and Net Income
From Biote
Via Business Wire
Biote Reports Second Quarter 2022 Financial Results
From Biote
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.